JAMA published results from the HARMONi-A randomized clinical trial assessing ivonescimab combined with chemotherapy in EGFR-variant non–small cell lung cancer. The report adds to the evidence base for bispecific antibodies paired with standard cytotoxic backbones, and it provides efficacy and safety context across trial arms. For clinicians and drug developers, the key question is whether antibody-driven immune engagement can maintain activity without introducing new tolerability constraints that would limit combination dosing. Trial-level subgrouping and endpoint behavior will determine how soon this strategy could influence line-of-therapy decisions. As bispecifics expand beyond early development, randomized data like this become central to differentiating which mechanisms can translate into durable benefit.